| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Peter Schmidt | Q57631064 |
| Johannes-Peter Stasch | Q66360867 | ||
| P2093 | author name string | György Haskó | |
| Harald H H W Schmidt | |||
| Oleg V Evgenov | |||
| Pál Pacher | |||
| P2860 | cites work | Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase. | Q44673838 |
| A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats | Q44804356 | ||
| The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. | Q44810227 | ||
| Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition | Q45069627 | ||
| Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs | Q45091740 | ||
| Femtomolar sensitivity of a NO sensor from Clostridium botulinum. | Q45096466 | ||
| Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects | Q45166624 | ||
| Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. | Q45193709 | ||
| Efficacy and optimal dose of sildenafil in primary pulmonary hypertension | Q45274674 | ||
| Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. | Q46032266 | ||
| BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump | Q46406343 | ||
| Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells | Q46427835 | ||
| Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase | Q46476857 | ||
| Membrane association of nitric oxide-sensitive guanylyl cyclase in cardiomyocytes. | Q46544029 | ||
| Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. | Q46554951 | ||
| Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition | Q46622392 | ||
| YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. | Q46720467 | ||
| Disturbances in nitric oxide/cyclic guanosine monophosphate system in SHR/NDmcr-cp rats, a model of metabolic syndrome | Q46723925 | ||
| Human soluble guanylate cyclase: functional expression and revised isoenzyme family | Q24314629 | ||
| Ancient conserved domains shared by animal soluble guanylyl cyclases and bacterial signaling proteins | Q24798253 | ||
| Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS | Q27748762 | ||
| Coronary-artery stents | Q28295059 | ||
| Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase | Q28379365 | ||
| Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme | Q28379416 | ||
| Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes | Q28565964 | ||
| Synaptic localization of nitric oxide synthase and soluble guanylyl cyclase in the hippocampus | Q28573791 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms | Q29619683 | ||
| NO/redox disequilibrium in the failing heart and cardiovascular system | Q30475784 | ||
| Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase | Q31805259 | ||
| NO-independent regulatory site on soluble guanylate cyclase | Q32165040 | ||
| Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats | Q33178899 | ||
| Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis | Q33209298 | ||
| Increased nitrovasodilator sensitivity in endothelial nitric oxide synthase knockout mice: role of soluble guanylyl cyclase. | Q33887169 | ||
| Tonic and acute nitric oxide signaling through soluble guanylate cyclase is mediated by nonheme nitric oxide, ATP, and GTP | Q33948069 | ||
| YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components | Q33948966 | ||
| Identification of the enzymatic mechanism of nitroglycerin bioactivation | Q34032459 | ||
| Pharmacology of penile erection | Q34090426 | ||
| Revisiting the kinetics of nitric oxide (NO) binding to soluble guanylate cyclase: the simple NO-binding model is incorrect | Q34155309 | ||
| Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. | Q34312771 | ||
| Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. | Q34401845 | ||
| Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide | Q40975817 | ||
| Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission | Q41082098 | ||
| Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats | Q41903134 | ||
| A-350619: a novel activator of soluble guanylyl cyclase | Q42049434 | ||
| Inhibition of soluble guanylate cyclase by ODQ. | Q42055822 | ||
| Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione s-transferase affinity tag. | Q42058515 | ||
| Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity | Q42099241 | ||
| YC-1, a novel activator of platelet guanylate cyclase | Q42275468 | ||
| Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one | Q42275867 | ||
| Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators | Q42435281 | ||
| Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis | Q42471113 | ||
| Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis | Q42479831 | ||
| Soluble guanylate cyclase: an old therapeutic target re-visited. | Q43263737 | ||
| Soluble guanylate cyclase alpha(1) and beta(1) gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects | Q43515684 | ||
| NO-independent stimulators of soluble guanylate cyclase | Q43558550 | ||
| Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo | Q43610465 | ||
| Upregulation of vascular NAD(P)H oxidase subunit gp91phox and impairment of the nitric oxide signal transduction pathway in hypertension | Q43691461 | ||
| Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents | Q43770043 | ||
| cGMP signalling beyond nitric oxide | Q43791947 | ||
| Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide | Q43911622 | ||
| Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase | Q43950505 | ||
| Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. | Q43961522 | ||
| Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. | Q43972677 | ||
| Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide | Q44000686 | ||
| YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats | Q44260144 | ||
| A stimulatory role for cGMP-dependent protein kinase in platelet activation | Q44277303 | ||
| BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. | Q44289016 | ||
| Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure | Q44310085 | ||
| BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo | Q44322931 | ||
| Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase | Q44445674 | ||
| NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis | Q44503836 | ||
| Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272. | Q44587860 | ||
| Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum | Q44602629 | ||
| Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery | Q44609195 | ||
| Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase | Q44626758 | ||
| The design and synthesis of YC-1 analogues as probes for soluble guanylate cyclase | Q46834469 | ||
| Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase | Q46839590 | ||
| Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling | Q46877903 | ||
| Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms | Q46877927 | ||
| Alterations of the vascular and the myocardial guanylate cyclase/cGMP-system induced by long-term hypertension in rats | Q47672866 | ||
| Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide | Q47910766 | ||
| Exchange of substrate and inhibitor specificities between adenylyl and guanylyl cyclases | Q47954577 | ||
| The burden of adult hypertension in the United States 1999 to 2000: a rising tide. | Q50143429 | ||
| Modulation of nitric oxide-dependent relaxation of pig tracheal smooth muscle by inhibitors of guanylyl cyclase and calcium activated potassium channels. | Q50766515 | ||
| Novel actions of methylene blue. | Q50778865 | ||
| Drug discovery technology Europe 2006 - IBC's Tenth Annual Conference and Exhibition. | Q50779782 | ||
| Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. | Q51189384 | ||
| Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. | Q51398065 | ||
| YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. | Q52981674 | ||
| A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits. | Q53005214 | ||
| The use of nitric oxide donors in pharmacological studies. | Q53947007 | ||
| Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. | Q54240963 | ||
| Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. | Q55663138 | ||
| BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats | Q58351224 | ||
| Pulmonary Arterial Hypertension | Q58485998 | ||
| Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms | Q69878955 | ||
| FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty | Q70860220 | ||
| Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase | Q71239563 | ||
| Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients | Q71571212 | ||
| Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study | Q72641848 | ||
| Functions of conserved cysteines of soluble guanylyl cyclase | Q73139586 | ||
| A point-mutated guanylyl cyclase with features of the YC-1-stimulated enzyme: implications for the YC-1 binding site? | Q73187839 | ||
| YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation | Q73300111 | ||
| Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase | Q73371570 | ||
| Interaction of soluble guanylate cyclase with YC-1: kinetic and resonance Raman studies | Q73626067 | ||
| Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study | Q74532201 | ||
| Formation of reactive oxygen species by pentaerithrityltetranitrate and glyceryl trinitrate in vitro and development of nitrate tolerance | Q77053822 | ||
| The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation | Q78038211 | ||
| Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats | Q83190387 | ||
| Functional characterization of two nucleotide-binding sites in soluble guanylate cyclase | Q83929538 | ||
| Taming platelets with cyclic nucleotides | Q34436565 | ||
| Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene | Q34693858 | ||
| Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels | Q35009484 | ||
| Comparison of two soluble guanylyl cyclase inhibitors, methylene blue and ODQ, on sodium nitroprusside-induced relaxation in guinea-pig trachea | Q35028147 | ||
| Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies | Q35044037 | ||
| Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies | Q35044042 | ||
| NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle | Q35044464 | ||
| The Rho-kinase inhibitor Y-27632 and the soluble guanylyl cyclase activator BAY41-2272 relax rabbit vaginal wall and clitoral corpus cavernosum | Q35044932 | ||
| Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase | Q35124292 | ||
| Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application | Q35206512 | ||
| Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide | Q35767797 | ||
| Recent advances in natriuretic peptides in congestive heart failure | Q35790792 | ||
| Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential | Q35822606 | ||
| Salutary properties of YC-1 in the cardiovascular and hematological systems | Q35867325 | ||
| YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase | Q35872795 | ||
| Specificity of different organic nitrates to elicit NO formation in rabbit vascular tissues and organs in vivo | Q35873058 | ||
| Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. | Q36018283 | ||
| A heretical view on the role of NO and cGMP in vascular proliferative diseases | Q36032424 | ||
| Nitrosative stress and pharmacological modulation of heart failure | Q36145124 | ||
| ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G | Q36259700 | ||
| Explaining the phenomenon of nitrate tolerance | Q36272905 | ||
| Activation of purified soluble guanylate cyclase by protoporphyrin IX. | Q36293899 | ||
| Function of cGMP-dependent protein kinases as revealed by gene deletion. | Q36350063 | ||
| Antifibrotic agents for liver disease | Q36376477 | ||
| Pharmacological management of renal fibrotic disease | Q36407348 | ||
| A molecular basis for nitric oxide sensing by soluble guanylate cyclase | Q36774286 | ||
| A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cells | Q37089466 | ||
| Human recombinant soluble guanylyl cyclase: expression, purification, and regulation | Q37259340 | ||
| Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases | Q37511692 | ||
| Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis | Q37692538 | ||
| Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation | Q37926154 | ||
| NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy | Q38758203 | ||
| Expression and characterization of the catalytic domains of soluble guanylate cyclase: interaction with the heme domain | Q39369792 | ||
| NO activation of guanylyl cyclase | Q40327686 | ||
| Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activation. | Q40354874 | ||
| A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. | Q40446987 | ||
| Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. | Q40569818 | ||
| Physiology of penile erection | Q40576740 | ||
| NO at work | Q40630836 | ||
| Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. | Q40735472 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 755-68 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | |
| P478 | volume | 5 |
| Q51522061 | (1)H, (13)C, (15)N backbone and side-chain resonance assignment of Nostoc sp. C139A variant of the heme-nitric oxide/oxygen binding (H-NOX) domain. |
| Q37820206 | A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction |
| Q49718583 | A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. |
| Q35743176 | A new small molecule inhibitor of soluble guanylate cyclase |
| Q54357894 | A novel insight into the heme and NO/CO binding mechanism of the alpha subunit of human soluble guanylate cyclase. |
| Q64069313 | A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation |
| Q36734217 | Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality |
| Q41329824 | Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway |
| Q46556756 | Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice. |
| Q35665739 | Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease |
| Q33738631 | Addressing the challenges of phenotyping pediatric pulmonary vascular disease |
| Q38959942 | Agents with vasodilator properties in acute heart failure |
| Q28084239 | Agents with vasodilator properties in acute heart failure: how to design successful trials |
| Q36949436 | Aging does not affect soluble guanylate cyclase redox state in mouse aortas |
| Q40642230 | Allostery in recombinant soluble guanylyl cyclase from Manduca sexta |
| Q34627792 | Alternative splicing impairs soluble guanylyl cyclase function in aortic aneurysm |
| Q46607492 | An enzyme-linked receptor mechanism for nitric oxide-activated guanylyl cyclase |
| Q36674593 | Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat |
| Q42863913 | Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase |
| Q37193830 | Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells |
| Q38014563 | Application of nitric oxide in drug discovery and development |
| Q36881722 | Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521) |
| Q36881704 | Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). |
| Q35210863 | BAY 41-2272 activates host defence against local and disseminated Candida albicans infections |
| Q51185201 | BAY 41-2272, a soluble guanylate cyclase stimulator, relaxes isolated human ureter in a standardized in vitro model. |
| Q46029902 | BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. |
| Q59885169 | Bacterial denitrifying nitric oxide reductases and aerobic respiratory terminal oxidases use similar delivery pathways for their molecular substrates |
| Q33849207 | Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies |
| Q41861837 | Binding of YC-1 or BAY 41-2272 to soluble guanylyl cyclase induces a geminate phase in CO photolysis |
| Q36881733 | Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food |
| Q33573360 | Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent |
| Q26771999 | Breakthrough in heart failure with preserved ejection fraction: are we there yet? |
| Q35204828 | Cardiac NO signalling in the metabolic syndrome |
| Q26853363 | Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction |
| Q36424922 | Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice |
| Q26751153 | Cerebral Small Vessel Disease: Targeting Oxidative Stress as a Novel Therapeutic Strategy? |
| Q30315850 | Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats |
| Q35658509 | Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice |
| Q41330819 | Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats |
| Q37419185 | Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload |
| Q35543584 | Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension |
| Q37343908 | Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus |
| Q57628743 | Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes |
| Q26775925 | Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update |
| Q58696712 | Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains |
| Q42075795 | Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. |
| Q27679506 | Crystal structure of the Alpha subunit PAS domain from soluble guanylyl cyclase |
| Q37688167 | Current and future therapy for pulmonary hypertension in patients with right and left heart failure |
| Q37420916 | Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics |
| Q34277031 | Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection |
| Q38043810 | Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension |
| Q39463724 | Cyclic stretch induces inducible nitric oxide synthase and soluble guanylate cyclase in pulmonary artery smooth muscle cells |
| Q54338197 | Delayed phospholamban phosphorylation in post-conditioned heart favours Ca2+ normalization and contributes to protection. |
| Q91027944 | Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model |
| Q42787506 | Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans |
| Q34957241 | Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension |
| Q47313531 | Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase |
| Q37550688 | Dissociation of hyperglycemia from altered vascular contraction and relaxation mechanisms in caveolin-1 null mice |
| Q39847509 | Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation |
| Q47939438 | Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats |
| Q36881692 | Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521) |
| Q46675366 | Effects of hydrogen peroxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries |
| Q33901272 | Endogenous NO upon estradiol-17β stimulation and NO donor differentially regulate mitochondrial S-nitrosylation in endothelial cells |
| Q41974344 | Endothelin-1 and endothelin-2 initiate and maintain contractile responses by different mechanisms in rat mesenteric and cerebral arteries |
| Q96304590 | Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator |
| Q38244605 | Evaluating the Phase II drugs currently under investigation for diabetic neuropathy |
| Q90678092 | Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction |
| Q26801173 | Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease |
| Q41225554 | Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer |
| Q27021649 | Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS |
| Q34433634 | Female sexual dysfunction: therapeutic options and experimental challenges. |
| Q28741339 | Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells |
| Q33640041 | Fluorescent fusion proteins of soluble guanylyl cyclase indicate proximity of the heme nitric oxide domain and catalytic domain |
| Q42600835 | Gaseotransmitters: new frontiers for translational science |
| Q46702844 | Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice |
| Q27001632 | Genetic modification of hypertension by sGCα1 |
| Q36005369 | Genetic modifiers of hypertension in soluble guanylate cyclase α1-deficient mice |
| Q37641083 | Good stress, bad stress--the delicate balance in the vasculature |
| Q89660045 | Guanylyl Cyclase-cGMP Signaling Pathway in Melanocytes: Differential Effects of Altered Gravity in Non-Metastatic and Metastatic Cells |
| Q51687813 | Guanylyl cyclase activation reverses resistive breathing-induced lung injury and inflammation. |
| Q42030989 | Heat shock protein 90 regulates stabilization rather than activation of soluble guanylate cyclase |
| Q34214656 | Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation |
| Q30539237 | Higher-order interactions bridge the nitric oxide receptor and catalytic domains of soluble guanylate cyclase. |
| Q100635461 | Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases |
| Q38991916 | Hydrogen sulfide, an enhancer of vascular nitric oxide signaling: mechanisms and implications |
| Q33818129 | Hypoxia induces downregulation of soluble guanylyl cyclase β1 by miR-34c-5p |
| Q60922875 | Identification of Candidate miRNA Biomarkers for Glaucoma |
| Q47661369 | Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease |
| Q44105235 | Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP. |
| Q36906999 | Impact of individual metabolic risk components or its clustering on endothelial and smooth muscle cell function in men. |
| Q51096085 | Impact of type 2 diabetes on vascular reactivity to cGMP generators in human internal thoracic arteries. |
| Q38680121 | Importance of kynurenine in pulmonary hypertension. |
| Q43184933 | In vitro and in vivo studies on the importance of the soluble guanylyl cyclase α1 subunit in penile erection |
| Q42946648 | Induction of PDE5 and de-sensitization to endogenous NO signaling in a systemic resistance artery under altered blood flow |
| Q36330594 | Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation |
| Q42951381 | Inhibition of nitric oxide-activated guanylyl cyclase by calmodulin antagonists. |
| Q26738907 | Innovative trends and perspectives for erectile dysfunction treatment: A systematic review |
| Q41770411 | Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat |
| Q27677544 | Insights into BAY 60-2770 Activation and S -Nitrosylation-Dependent Desensitization of Soluble Guanylyl Cyclase via Crystal Structures of Homologous Nostoc H-NOX Domain Complexes |
| Q27680135 | Insights into Soluble Guanylyl Cyclase Activation Derived from Improved Heme-Mimetics |
| Q27001165 | Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy |
| Q46261374 | Irreversible activation and stabilization of soluble guanylate cyclase by the protoporphyrin IX mimetic cinaciguat. |
| Q34039950 | Is Nostoc H-NOX a NO sensor or redox switch? |
| Q37481343 | Leads for the treatment of pulmonary hypertension |
| Q37634112 | Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia |
| Q46280862 | Lung Ischaemia-Reperfusion Injury: The Role of Reactive Oxygen Species |
| Q57300061 | Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats |
| Q36674960 | Mechanisms controlling vascular tone in pulmonary arterial hypertension: implications for vasodilator therapy |
| Q38126948 | Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy |
| Q37329891 | Modulation of cGMP in heart failure: a new therapeutic paradigm |
| Q42497527 | Modulation of growth cone filopodial length by carbon monoxide |
| Q38118626 | Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction |
| Q36713981 | Molecular model of a soluble guanylyl cyclase fragment determined by small-angle X-ray scattering and chemical cross-linking |
| Q35378266 | Motion of proximal histidine and structural allosteric transition in soluble guanylate cyclase |
| Q52687612 | Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. |
| Q27641107 | NO and CO differentially activate soluble guanylyl cyclase via a heme pivot-bend mechanism |
| Q46040106 | NO-independent activators of soluble guanylate cyclase: therapeutic potential. |
| Q35375986 | NOX1, 2, 4, 5: counting out oxidative stress |
| Q36794409 | Natriuretic peptides and therapeutic applications |
| Q60919681 | New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease |
| Q27021422 | New insights into the role of soluble guanylate cyclase in blood pressure regulation |
| Q38594785 | New medical therapies for heart failure |
| Q37724192 | New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation |
| Q38412804 | Nitric Oxide Regulates Skeletal Muscle Fatigue, Fiber Type, Microtubule Organization, and Mitochondrial ATP Synthesis Efficiency Through cGMP-Dependent Mechanisms |
| Q35884072 | Nitric Oxide Resistance Reduces Arteriovenous Fistula Maturation in Chronic Kidney Disease in Rats |
| Q52738823 | Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease. |
| Q24645400 | Nitric oxide and peroxynitrite in health and disease |
| Q52710382 | Nitric oxide stimulates human neural progenitor cell migration via cGMP-mediated signal transduction. |
| Q42467382 | Nitric oxide targets oligodendrocytes and promotes their morphological differentiation |
| Q37669139 | Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension |
| Q35596709 | Nitric oxide-cyclic GMP signaling in stem cell differentiation |
| Q37887771 | Nitric oxide: a guardian for vascular grafts? |
| Q37927098 | Nitric oxide: orchestrator of endothelium-dependent responses |
| Q34233761 | Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation |
| Q96609757 | Non-canonical chemical feedback self-limits nitric oxide-cyclic GMP signaling in health and disease |
| Q38856565 | Non-nitric oxide based metallovasodilators: synthesis, reactivity and biological studies |
| Q39024203 | Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure |
| Q37179695 | Novel therapies for cyclic GMP control of vascular smooth muscle growth |
| Q38072635 | Novel vasodilators in heart failure |
| Q37342409 | Nucleotide regulation of soluble guanylate cyclase substrate specificity |
| Q46868100 | Opposing effects of coupled and uncoupled NOS activity on the Na+-K+ pump in cardiac myocytes. |
| Q28247831 | Oxidative stress associated with middle aging leads to sympathetic hyperactivity and downregulation of soluble guanylyl cyclase in corpus cavernosum |
| Q28262626 | PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells |
| Q36532454 | Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling |
| Q45928887 | Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls. |
| Q40386143 | Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study |
| Q34823612 | Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers |
| Q58603529 | Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery |
| Q47133234 | Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation |
| Q26785525 | Pharmacology and Clinical Drug Candidates in Redox Medicine |
| Q34341399 | Phosphodiesterase 2A is a major negative regulator of iNOS expression in lipopolysaccharide-treated mouse alveolar macrophages |
| Q42555438 | Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production. |
| Q42645453 | Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure |
| Q37476512 | Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice |
| Q36178862 | Pretreatment with β-Boswellic Acid Improves Blood Stasis Induced Endothelial Dysfunction: Role of eNOS Activation. |
| Q37660997 | Probing the Molecular Mechanism of Human Soluble Guanylate Cyclase Activation by NO in vitro and in vivo |
| Q35107626 | Probing the local electronic and geometric properties of the heme iron center in a H-NOX domain |
| Q39504233 | Probing the presence of the ligand-binding haem in cellular nitric oxide receptors |
| Q36693586 | Protoporphyrin IX/Cobyrinate Derived Hybrids - Novel Activators of Soluble Guanylyl Cyclase |
| Q87520772 | Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia |
| Q34212268 | Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide |
| Q38283873 | Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options |
| Q27024762 | Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications |
| Q37376997 | Reactive oxygen and nitrogen species in pulmonary hypertension |
| Q41983620 | Real-time monitoring the spatiotemporal dynamics of intracellular cGMP in vascular smooth muscle cells |
| Q47812722 | Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor |
| Q37697630 | Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow. |
| Q42361109 | Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide |
| Q58127035 | Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib-Induced Hypertension |
| Q38112048 | Right ventricle in pulmonary hypertension. |
| Q41166010 | Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study |
| Q33447738 | Riociguat (BAY 63–2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study |
| Q46211817 | Riociguat and cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats |
| Q37709398 | Riociguat for pulmonary hypertension |
| Q38192059 | Riociguat for pulmonary hypertension |
| Q37851516 | Riociguat for the treatment of pulmonary hypertension. |
| Q26748684 | Riociguat: Mode of action and clinical development in pulmonary hypertension |
| Q41980644 | Riociguat: PATENT-1 Study |
| Q38502798 | Riociguat: a novel new drug for treatment of pulmonary hypertension |
| Q37537154 | Role of guanylate cyclase modulators in decompensated heart failure |
| Q46486715 | Role of nitric oxide in the control of the pulmonary circulation: physiological, pathophysiological, and therapeutic implications |
| Q36999849 | Role of nitric oxide signaling components in differentiation of embryonic stem cells into myocardial cells. |
| Q36426742 | Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors |
| Q48270850 | Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat. |
| Q46562534 | Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers |
| Q87418632 | Small alterations in cobinamide structure considerably influence sGC activation |
| Q36887547 | Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface |
| Q53760527 | Soluble Guanylate Cyclase Modulators, BAY 41-2272 and BAY 60-2770, Inhibit Human and Rabbit Prostate Contractility. |
| Q38818645 | Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP? |
| Q36902247 | Soluble guanylate cyclase activation during ischemic injury in mice protects against postischemic inflammation at the mitochondrial level |
| Q34122462 | Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor |
| Q34618219 | Soluble guanylate cyclase alpha1beta1 limits stroke size and attenuates neurological injury. |
| Q36865999 | Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma |
| Q35010064 | Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease |
| Q37399819 | Soluble guanylate cyclase generation of cGMP regulates migration of MGE neurons |
| Q37826122 | Soluble guanylate cyclase modulators in heart failure |
| Q37303013 | Soluble guanylate cyclase redox state under oxidative stress conditions in isolated monkey coronary arteries |
| Q28742463 | Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats |
| Q47664739 | Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease. |
| Q27331498 | Soluble guanylate cyclase α1-deficient mice: a novel murine model for primary open angle glaucoma |
| Q35075847 | Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |
| Q38012596 | Soluble guanylate cyclase: a potential therapeutic target for heart failure |
| Q46403664 | Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress |
| Q37018298 | Soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice |
| Q48023073 | Soluble guanylyl cyclase is a critical regulator of migraine-associated pain |
| Q36167665 | Soluble guanylyl cyclase requires heat shock protein 90 for heme insertion during maturation of the NO-active enzyme |
| Q58075704 | Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation |
| Q46455331 | Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema |
| Q54375096 | Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling. |
| Q47603923 | Stimulators and activators of soluble guanylate cyclase for urogenital disorders |
| Q38000562 | Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. |
| Q38093420 | Stimulators of soluble guanylyl cyclase: future clinical indications |
| Q51682930 | Stimulators of the soluble guanylyl cyclase: promising functional insights from rare coding atherosclerosis-related GUCY1A3 variants. |
| Q38894826 | Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor |
| Q27661554 | Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase |
| Q38646890 | Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activators |
| Q58615248 | Synthesis and biological activity of furanylindazoles as inhibitors of hypoxia inducible factor (HIF)-1 transcriptional activity |
| Q35873815 | Synthetic Peptides as cGMP-Independent Activators of cGMP-Dependent Protein Kinase Iα |
| Q61136944 | Systemic control of immune cell development by integrated carbon dioxide and hypoxia chemosensation in Drosophila |
| Q38836199 | Targeting vascular (endothelial) dysfunction. |
| Q27308898 | The Receptor-Bound Guanylyl Cyclase DAF-11 Is the Mediator of Hydrogen Peroxide-Induced cGMP Increase in Caenorhabditis elegans [corrected] |
| Q38772751 | The Role of Reactive Oxygen and Nitrogen Species in the Expression and Splicing of Nitric Oxide Receptor |
| Q36031657 | The alpha1 isoform of soluble guanylate cyclase regulates cardiac contractility but is not required for ischemic preconditioning |
| Q34389020 | The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide |
| Q27024279 | The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction |
| Q38130465 | The chemistry and biology of soluble guanylate cyclase stimulators and activators |
| Q37703984 | The current and future management of acute heart failure syndromes |
| Q38896087 | The role of cGMP and its signaling pathways in kidney disease |
| Q34902456 | The role of heat shock protein 70 in the protective effect of YC-1 on β-amyloid-induced toxicity in differentiated PC12 cells. |
| Q48033453 | The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease |
| Q36923923 | The sGC activator BAY 60-2770 has potent erectile activity in the rat. |
| Q43119916 | The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood |
| Q34981386 | The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems |
| Q45925609 | The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. |
| Q55340936 | The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. |
| Q87445917 | The soluble guanylyl cyclase activator BAY 60-2770 potently relaxes the pulmonary artery on congenital diaphragmatic hernia rabbit model |
| Q26767305 | The treatment of erectile dysfunction in patients with neurogenic disease |
| Q51587859 | Therapeutic potential of soluble guanylate cyclase modulators in neonatal chronic lung disease. |
| Q30503997 | Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration |
| Q33772904 | Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase |
| Q37615958 | Translating the oxidative stress hypothesis into the clinic: NOX versus NOS. |
| Q26830290 | Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011 |
| Q37902509 | Treatment of pulmonary arterial hypertension with targeted therapies |
| Q37100702 | Update in pulmonary arterial hypertension 2007. |
| Q43073192 | Vascular biology and pathobiology of the liver: Report of a single-topic symposium |
| Q37725077 | Vascular dysfunction in cerebrovascular disease: mechanisms and therapeutic intervention |
| Q54185546 | Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm. |
| Q34432730 | Vascular smooth muscle phenotypic diversity and function |
| Q35086394 | Vasculopathy and pulmonary hypertension in sickle cell disease |
| Q37557818 | YC-1 binding to the β subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the α subunit. |
| Q41983813 | YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells |
| Q87460685 | [Cor pulmonale and pulmonary hypertension. Update after the world conference in Nice] |
| Q84164467 | [Interstitial lung diseases and pulmonary hypertension] |
| Q61799295 | as a Genetic Model for Hematopoiesis |
| Q58796764 | cGMP Imaging in Brain Slices Reveals Brain Region-Specific Activity of NO-Sensitive Guanylyl Cyclases (NO-GCs) and NO-GC Stimulators |
| Q52578398 | cGMP Signaling and Vascular Smooth Muscle Cell Plasticity. |
| Q55004774 | cGMP Signaling in the Cardiovascular System-The Role of Compartmentation and Its Live Cell Imaging. |
| Q54978990 | cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. |
| Q37002324 | cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines. |
| Q91996105 | sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH |
Search more.